Melanotan 2 (MT-2) Side Effects — Laboratory Research Reference

*Documented adverse-event profile of MT-2 in published case reports and pharmacology literature: nausea, blood-pressure flushing, nevi changes, priapism risk and dose–response considerations.*

Research Use Only. All material on this page is provided strictly for in vitro and in vivo laboratory research purposes. It is not medical advice and is not intended for human or veterinary therapeutic use. Researchers are responsible for compliance with all applicable laws, IRB/IACUC oversight and institutional biosafety policy.

Overview

Melanotan 2 (MT-2) is a synthetic α-MSH analogue with documented adverse events from case reports, dermatology literature and pharmacology studies. It is not approved for human use in any jurisdiction.

Documented Adverse Events

• Nausea / vomiting: the most common acute effect, typically within 30–90 min of dosing; melanocortin-mediated
• Facial flushing / blood-pressure changes: transient hypotension or hypertension reported
• Spontaneous penile erection / priapism: mechanism on-target (MC4R); priapism cases requiring intervention published
• Hyperpigmentation: generalised tanning is intended, but the literature documents new and darkening melanocytic nevi after MT-2 use — multiple case reports of melanoma diagnosed in users
• Loss of appetite: anorexigenic via MC4R
• Injection-site reactions: mild

Notable Case Reports

• Cardona-Rossinyol et al., 2014 — eruptive melanocytic nevi after MT-2 use
• Kelly et al., 2010 — melanoma in young MT-2 user
• Ong & Bowling, 2012 — change in pre-existing nevi after MT-2 injection
• Multiple case reports of priapism requiring emergent management

Mechanistic Context

MT-2 is a non-selective MC1R / MC3R / MC4R / MC5R agonist. The pigmentation effect is MC1R-mediated; nausea, appetite suppression and erectile activity are MC4R; cardiovascular and renal effects involve MC3R/MC5R. The non-selective receptor profile is the principal driver of the side-effect breadth.

Practical Research Considerations

Research protocols should include full dermatological imaging baselines, blood-pressure monitoring across the first hour post-dose, and pre-specified stopping rules for any pigmented-lesion change. Concurrent androgen administration appears to increase priapism risk in case-report literature.

Frequently Asked Research Questions

Why does MT-2 cause nausea?

Central MC4R activation produces dose-dependent nausea, typically within 30–90 minutes of subcutaneous administration; the effect attenuates with repeated exposure in most subjects.

Does MT-2 increase melanoma risk?

Published case reports describe new melanocytic nevi and melanoma diagnoses temporally associated with MT-2 use. Causality has not been established in a controlled trial, but the dermatology literature treats it as a meaningful research concern.

What is the priapism risk?

Multiple case reports describe priapism requiring emergent management, particularly when MT-2 is combined with PDE5 inhibitors or exogenous androgens. The MC4R agonism is the proposed mechanism.

References

1. Drucker DJ. *Mechanisms of action and therapeutic application of GLP-1.* Cell Metab. 2018.

1. Frias JP, et al. *Tirzepatide vs semaglutide once weekly.* N Engl J Med. 2021.

1. Jastreboff AM, et al. *Triple–hormone-receptor agonist retatrutide for obesity.* N Engl J Med. 2023.

1. Sikiric P, et al. *Stable gastric pentadecapeptide BPC 157 — review.* Curr Pharm Des. 2018.

1. Goldman MP. *Photoprotection and α-MSH analogues.* J Drugs Dermatol. 2010.

1. Teichman SL, et al. *Prolonged stimulation of GH and IGF-1 secretion by CJC-1295.* J Clin Endocrinol Metab. 2006.

1. Goldstein AL, Hannappel E. *Thymosin β4 — actin sequestering and tissue repair.* Ann N Y Acad Sci. 2007.

1. Pickart L, Margolina A. *Regenerative and protective actions of the GHK-Cu peptide.* Int J Mol Sci. 2018.